Japan’s regulator approved the world’s first induced pluripotent stem cell (iPSC)‑derived therapy for Parkinson’s disease, marking a regulatory first for iPSC‑based regenerative treatments and validating a pathway for cell therapies in neurodegeneration. The decision follows clinical development that met local safety and efficacy thresholds and leverages Japan’s early adoption of stem‑cell clinical frameworks. The approval provides a commercial and regulatory precedent that could accelerate investment into iPSC platforms and influence global development strategy for cell therapies targeting chronic neurodegenerative disorders. Companies and investors will monitor post‑market commitments and real‑world safety data closely as the therapy scales.